Home › Analyst: In Merck-Idenix deal, 'biggest question' is why Gilead wasn't the suitor
 

Keywords :   


Analyst: In Merck-Idenix deal, 'biggest question' is why Gilead wasn't the suitor

2014-06-18 21:04:16| Biotech - Topix.net

If Merck & Co .' s $4 billion bet on the hepatitis C drug being developed by Cambridge biotech firm Idenix Pharmaceuticals pays off, it will provide Merck with a slice of an estimated $50 billion market over the next decade.

Tags: the question deal biggest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
28.09Tropical Storm Joyce Forecast Advisory Number 5
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 11
More »